Dorzolamide Hydrochloride
FDA-approved product (solution/drops, ophthalmic), marketed as Dorzolamide Hydrochloride, Trusopt.
- Registered studies
- 50+
- Lab records
- 4
- Pathogens at ≥40%
- 2 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Glaucoma
- Ocular hypertension
- Open-angle glaucoma
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Carbonic anhydrase inhibitors
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA44.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli39.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae27.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis86.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
- M. tuberculosis: measured active in 4 of 4 lab records
Show the 4 laboratory records, with sources
Loading records…
“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Dorzolamide Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Cetrorelix AcetateExisting use: Ovulation Inhibition, Positive regulation of ovulation63.2% AI-predicted activityagainst MRSA50+ registered studies
- HexachloropheneExisting use: Phenol and derivatives63.2% AI-predicted activityagainst MRSALab records exist3 registered studies
- LorlatinibExisting use: Cancer, Lymphoma, Neoplasm and 1 more63.1% AI-predicted activityagainst MRSA50+ registered studies
- Alectinib HydrochlorideExisting use: Cancer, Neoplasm, Non-small cell lung carcinoma63.0% AI-predicted activityagainst MRSA13 registered studies
- AlpelisibExisting use: Breast cancer, Breast carcinoma, Breast neoplasm and 2 more63.0% AI-predicted activityagainst MRSA50+ registered studies
- Histrelin AcetateExisting use: Neoplasm, Prostate adenocarcinoma, Prostate cancer62.9% AI-predicted activityagainst MRSA13 registered studies
- Degarelix AcetateExisting use: Prostate adenocarcinoma, Prostate cancer, Prostate carcinoma62.9% AI-predicted activityagainst MRSA50+ registered studies
- Lasmiditan SuccinateExisting use: Migraine disorder62.8% AI-predicted activityagainst MRSANo documented evidence found
- TacrolimusExisting use: Atopic eczema, Delayed Graft Function, Eczematoid dermatitis and 3 more62.5% AI-predicted activityagainst MRSA50+ registered studies
- Rezafungin AcetateExisting use: Candidemia, Candidiasis, Candidiasis, Invasive62.4% AI-predicted activityagainst MRSA5 registered studies
- AvapritinibExisting use: Cancer, Gastrointestinal stromal tumor, Neoplasm62.2% AI-predicted activityagainst MRSA30 registered studies
- Ceruletide DiethylamineExisting use: Tests for bile duct patency62.2% AI-predicted activityagainst MRSANo documented evidence found
Registered studies
A registration describes a study; it does not establish a positive result.
Cosopt Versus Xalacom
NCT00273481 · start 2005-09
Registered record
- Registry ID
- NCT00273481
- Conditions
- Open-Angle Glaucoma; Ocular Hypertension
- Interventions
- dorzolamide 2%/timolol maleate 0.5% fixed combination; latanoprost 0.005%/timolol maleate 0.5% fixed combination; timolol maleate 0.5%; placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2005-09
- Completion
- 2007-04
- Enrolment
- 33
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionOpen-Angle Glaucoma; Ocular HypertensionInterventiondorzolamide 2%/timolol maleate 0.5% fixed combination; latanoprost 0.005%/timolol maleate 0.5% fixed combination; timolol maleate 0.5%; placeboPhasePhase 4Registry statusCompletedA 12week, Randomized, Evaluator-Masked, Parallel Group Comparing Evening Dosing Of Xalacom Vs Cosopt In Subj W/ Glaucoma
NCT00140049 · start 2005-07
Registered record
- Registry ID
- NCT00140049
- Conditions
- Glaucoma, Open Angle; Ocular Hypertension
- Interventions
- Xalacom; Cosopt
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2005-07
- Completion
- 2006-07
- Enrolment
- 238
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionGlaucoma, Open Angle; Ocular HypertensionInterventionXalacom; CosoptPhasePhase 4Registry statusCompletedComparison of the Fixed Combinations of Brimonidine/Timolol and Dorzolamide/Timolol in Subjects With Open-Angle Glaucoma or Ocular Hypertension
NCT00822055 · start 2005-05
Registered record
- Registry ID
- NCT00822055
- Conditions
- Open-Angle Glaucoma; Ocular Hypertension
- Interventions
- brimonidine tartrate 0.2%/timolol maleate 0.5% fixed combination; dorzolamide hcl 2%/timolol maleate 0.5% fixed combination; brimonidine tartrate 0.2%/timolol maleate 0.5% fixed combination as adjunctive to current prostaglandin therapy; dorzolamide hcl 2%/timolol maleate 0.5% fixed combination as adjunctive to current prostaglandin therapy
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2005-05
- Completion
- 2006-11
- Enrolment
- 140
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionOpen-Angle Glaucoma; Ocular HypertensionInterventionbrimonidine tartrate 0.2%/timolol maleate 0.5% fixed combination; dorzolamide hcl 2%/timolol maleate 0.5% fixed combination; brimonidine tartrate 0.2%/timolol maleate 0.5% fixed combination as adjunctive to current prostaglandin therapy; dorzolamide hcl 2%/timolol maleate 0.5% fixed combination as adjunctive to current prostaglandin therapyPhasePhase 4Registry statusCompletedComparison of the Fixed Combinations of Brimonidine/Timolol and Dorzolamide/Timolol in Subjects With Open-Angle Glaucoma or Ocular Hypertension
NCT00822081 · start 2005-01
Registered record
- Registry ID
- NCT00822081
- Conditions
- Open-Angle Glaucoma; Ocular Hypertension
- Interventions
- brimonidine tartrate 0.2%/timolol maleate 0.5% fixed combination; dorzolamide hcl 2%/ timolol maleate 0.5% fixed combination; brimonidine tartrate 0.2%/timolol maleate 0.5% fixed combination as adjunctive to current prostaglandin therapy.; dorzolamide hcl 2%/timolol maleate 0.5% fixed combinatin as adjunctive to current prostaglandin therapy.
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2005-01
- Completion
- 2006-04
- Enrolment
- 140
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionOpen-Angle Glaucoma; Ocular HypertensionInterventionbrimonidine tartrate 0.2%/timolol maleate 0.5% fixed combination; dorzolamide hcl 2%/ timolol maleate 0.5% fixed combination; brimonidine tartrate 0.2%/timolol maleate 0.5% fixed combination as adjunctive to current prostaglandin therapy.; dorzolamide hcl 2%/timolol maleate 0.5% fixed combinatin as adjunctive to current prostaglandin therapy.PhasePhase 4Registry statusCompletedA Comparison of the Effect of Dorzolamide and Timolol on Optic Disk Blood Flow in Patients With Open Angle Glaucoma
NCT00991822 · start 1999-05
Registered record
- Registry ID
- NCT00991822
- Conditions
- Glaucoma, Open-Angle
- Interventions
- Dorzolamide 2%; Timolol 0.5%
- Study type
- INTERVENTIONAL
- Phase
- Phase 2 / Phase 3
- Registry status
- Completed
- Start
- 1999-05
- Completion
- 2003-12
- Enrolment
- 160
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionGlaucoma, Open-AngleInterventionDorzolamide 2%; Timolol 0.5%PhasePhase 2 / Phase 3Registry statusCompleted